Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Pfizer

The Biden administration said it expects the new Pfizer and Moderna vaccines targeting the omicron variant XBB.1.5 to be available in mid-September.

FDA approves updated Covid vaccines from Pfizer and Moderna as hospitalizations rise

Immatics NV

Immatics NV's shares rose Monday after it announced a collaboration with Moderna Therapeutics Inc (NASDAQ:MRNA) to pioneer novel and transformative therapies for cancer patients with high unmet medical need. Under the agreement, the German drug developer will receive an upfront payment of $120 million.

Immatics inks deal worth $120M to $1.7B with Moderna to boost cancer vaccine development

Immatics NV shares IMTX, -2.87% gained more than 6% premarket on Monday after the company announced a collaboration with Moderna Inc. MRNA, -0.66% to research and develop new cancer therapies. The partnership couples Immatics' T cell-redirecting cancer immunotherapy platform with Moderna's mRNA technology and is expected to span bispecifics, cell therapy and cancer vaccines, the companies said in a release Monday.

Immatics shares rise on Moderna cancer collaboration

Vaccine maker Moderna said on Monday it had struck a deal with Immatics for developing cancer vaccines and therapies and would pay the drug developer $120 million in cash and additional milestone payments.

Moderna, Immatics to work jointly on cancer vaccines

Cambridge, Massachusetts and Tuebingen , Germany , September 11 , 2023 – Moderna, Inc. (NASDAQ: MRNA, “Moderna”) and Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need. This broad multi-platform collaboration will leverage the deep scientific expertise and core operational capabilities of both companies, combining Immatics' TCR platform with Moderna's cutting-edge mRNA technology, and span various therapeutic modalities including bispecifics, cell therapy and cancer vaccines.

Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules Companies to leverage Immatics' XPRESIDENT® target discovery platform and Moderna's mRNA technology for the development of novel cancer vaccines Collaboration to include evaluation of Immatics' investigational IMA203 PRAME TCR-T in combination with Moderna's investigational PRAME mRNA cancer vaccine Immatics to receive $120 million upfront cash payment plus research funding with the potential for additional milestone and royalty payments CAMBRIDGE, MA and TUEBINGEN, GERMANY / ACCESSWIRE / September 11, 2023 / Moderna, Inc. (NASDAQ:MRNA, "Moderna") and Immatics N.V. (NASDAQ:IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need.

Moderna & Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

Denali Therapeutics

Foghorn Therapeutics

Seres Therapeutics

Omega Therapeutics

Sana Biotechnology

CAMBRIDGE, Mass. , Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Development Officer.

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

Apple

The Consumer Price Index is expected to be up 3.6%. Results from Oracle, Adobe, and Lennar.

Apple, Moderna, Inflation, and More to Watch This Week

Quad/Graphics

Take-Two Interactive Software

It's the question everybody wants to know: Are meme stocks dead? Well, according to an August report from the Associated Press, apparently not.

3 Meme Stocks That Could Actually Rebound in Q4

CAMBRIDGE, MA / ACCESSWIRE / September 8, 2023 / Moderna, Inc. (Nasdaq:MRNA) has been notified that TRC Capital Investment Corporation (TRC Capital) has made an unsolicited "mini-tender" offer to purchase up to 1,000,000 shares of Moderna's common stock, at an offer price of $107.56 per share. TRC Capital's offer price of $107.56 per share is approximately 4.44% lower than the closing price of Moderna common stock on the Nasdaq Global Select Market on September 1, 2023, the last trading day prior to the date of the offer, September 5, 2023.

Moderna Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation

Investors have shied away from Moderna in recent times as demand for its one and only product -- the coronavirus vaccine -- declines. But that particular product could be the driving force behind a whole new phase of revenue to come.

COVID Vaccine Sales Are Declining. But Here's How They're Still Driving Growth at Moderna.

Amazon

Intuitive Surgical

Despite bouncing 42% (year-to-date) through the end of August, the Nasdaq 100 still sits 7% below its all-time high. Two Nasdaq 100 components have well-defined moats within their specific industries that should cultivate a sustained double-digit growth rate.

2 Nasdaq 100 Stocks That Are Surefire Buys in September and 1 to Avoid Like the Plague

Clinical study data shows Moderna's (MRNA) updated COVID-19 vaccine generates a robust immune response against newer circulating variants, including Pirola and Eris.

Moderna (MRNA) Updated COVID Jab Effective Against Pirola Variant

Novavax

The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting on updated COVID-19 vaccines at a meeting scheduled for September 12, 2023.

3 Stocks to Buy For the COVID Resurgence

Hookipa Pharma Inc

Invivyd Inc

Seelos Therapeutics

Zomedica

Amyris Inc

Investing in biotech stocks is not for the meek. Losses can be very large and occur very quickly.

7 Biotech Stocks to Sell in September Before They Crash & Burn

CAMBRIDGE, MA / ACCESSWIRE / September 6, 2023 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in a fireside chat at Morgan Stanley's 21st Annual Global Healthcare Conference on Tuesday, September 12th at 12:15 p.m. ET. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com.

Moderna to Participate at Morgan Stanley 21st Annual Global Healthcare Conference

Is Moderna stock a buy as the company looks to launch an updated Covid vaccine? Is MRNA stock a buy right now?

Is Moderna Stock A Buy As It Looks To Take On The Highly Mutated 'Pirola' Variant?

Moderna stock slipped Wednesday after the company said its updated Covid vaccine can take on a highly mutated strain nicknamed "pirola."

Here's How Moderna's Updated Covid Shot Stacks Up Against Highly Mutated 'Pirola' Variant

Moderna Therapeutics Inc (NASDAQ:MRNA) has told investors that its revised Covid vaccine appears effective against the BA.2.86 subvariant, a highly mutated form of the coronavirus. Clinical trials revealed an 8.7-fold surge in neutralizing antibodies against this subvariant, which is closely monitored by global health agencies like the WHO and the CDC.

Moderna vaccine effective against latest Covid strain

The news comes amid concerns about rising cases in the U.S.

Moderna Stock Gains. Its Vaccine Is Effective Against New Covid Strain.

Moderna Inc. MRNA on Wednesday released clinical trial data indicating that its updated COVID-19 vaccination is effective against the BA.2.86 Pirola variant, which is being closely monitored by researchers due to concerns that it could more easily break through existing immunity. The new shot showed an 8.7 to 11-fold increase in neutralizing antibodies against BA.2.86 and other circulating variants, including the EG.5 Eris variant and FL.1.5.1, Moderna said in a release.

Moderna says updated COVID vaccine effective against BA.2.86 Pirola variant

Experts are worried the highly mutated variant, a relative of omicron formally called BA.2.86, could trigger a new wave of cases.

Moderna's Updated Covid Vaccine Is Effective Against Pirola Variant—As Concern Over New Strain Grows

Moderna on Wednesday said clinical trial data showed its updated COVID-19 vaccine will likely be effective against the highly-mutated BA.2.86 subvariant of the coronavirus that has raised fears of a resurgence of infections.

Moderna says updated COVID vaccine is effective against newer variant

Moderna, Pfizer and Novavax are slated to roll out new vaccines targeting XBB.1.5 within weeks, pending approvals from the FDA.

Moderna says updated Covid vaccine was effective against highly mutated BA.2.86 variant in trial

CDC notes that the BA.2.86 (Pirola) variant may be more likely to break through existing immunity from previous vaccination or infection, highlighting the need for vaccination with an updated COVID-19 vaccine for the fall 2023 season Clinical trial data from research assay confirmed Moderna's updated COVID-19 vaccine showed an 8.7 to 11-fold increase in neutralizing antibodies against circulating variants, including BA.2.86, EG.5, and FL.1.5.1 variants With governments accelerating the timing of COVID-19 vaccination campaigns due to the potential risk of BA.2.86, Moderna has shared this data with regulators and is ready to supply its updated COVID-19 vaccine pending regulatory approval CAMBRIDGE, MA / ACCESSWIRE / September 6, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced that clinical trial data from its research assay confirm its updated COVID-19 vaccine, which is pending approval by the U.S. Food and Drug Administration for the fall 2023 vaccination season, generates an 8.7-fold increase in neutralizing antibodies in humans against BA.2.86 (Pirola), a variant under monitoring. The Centers for Disease Control (CDC) indicates that the highly mutated BA.2.86 variant may be more capable of causing infection in people who previously had COVID-19 or were vaccinated with previous vaccines, noting that updated COVID-19 vaccines may be effective in reducing severe disease and hospitalization.

News for Moderna Stock (MRNA)